DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Six-Week Safety Study of an Investigational Ophthalmic Solution

Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Allergic Conjunctivitis

Intervention: AL-4943A Ophthalmic Solution (Drug); AL-4943A Ophthalmic Solution Vehicle (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Alcon Research

Official(s) and/or principal investigator(s):
Terri Pasquine, Study Director, Affiliation: Alcon Research


The purpose of this study was to evaluate the ocular safety of an investigational ophthalmic solution in subjects 2 years of age and older with asymptomatic eyes when administered once daily in both eyes for up to 6 weeks.

Clinical Details

Official title: A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AL-4943A Ophthalmic Solution Administered Once Daily

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)

Primary outcome: Adverse Events


Minimum age: 2 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Able and willing to comply with study protocol and follow protocol instructions.

- Adequate birth control methods for the duration of the study.

- Best-corrected visual acuity (BCVA) of 55 or greater in each eye.

- Willing to avoid contact lens wear during each of the study visits; contact lens wear

also should be stable and consistent for 1 month prior to Visit 1 and expected to remain the same for the study duration.

- Willing and able to sign an Informed Consent form.

- Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

- Women of childbearing potential that are pregnant, breastfeeding, or not in agreement

to use adequate birth control methods to prevent pregnancy throughout the study.

- Evidence of contact lens care solution related ocular surface damage or giant

papillary conjunctivitis (GPC).

- Any ocular infection (bacterial, viral or fungal) or history of ocular Herpes

(simplex or zoster) or adenoviral infection in either eye or have had any ocular infection within 30 days prior to Visit 1.

- Using systemic medication(s) on a chronic dosing regimen for less than 30 days or

changed dosage of this medication within 30 days prior to Visit 1.

- Current or past history of glaucoma or ocular hypertension.

- History of retinal detachment, diabetic retinopathy, or progressive retinal disease.

- Presence of ocular conditions that may affect the study outcomes.

- Corneal conditions affecting the corneal structure.

- History or evidence of any ocular surgical procedure within 1 year prior to Visit 1.

- Current or recent medical conditions that, in the opinion of the Investigator, would

preclude safe participation in the study.

- Prior, current, or anticipated use of ophthalmic agents other than investigational

product during study participation.

- Participation in any investigational study within 30 days prior to Visit 1 or

concomitantly with this study.

- Known contraindications or hypersensitivities to any of the study medications or

their components.

- Other protocol-specified exclusion criteria may apply.

Locations and Contacts

Additional Information

Starting date: October 2012
Last updated: February 27, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017